MS329 SWITCHING FROM ANY STATIN BRAND TO EZETIMIBE/SIMVASTATIN 10/20 mg IS MORE EFFECTIVE AT LOWERING PLASMA LIPIDS VERSUS ROSUVASTATIN 10 mg

Autor:	L.M. Viigimaa, Q. Dong, Michel Farnier, William Taggart, Arvind Shah, Amy O. Johnson-Levonas, Philippe Brudi, Maurizio Averna, Helena Vaverkova, Luc Missault
Rok vydání:	2010
Předmět:	Statin medicine.drug_class business.industry Plasma lipids Internal Medicine medicine Ezetimibe/simvastatin Rosuvastatin General Medicine Pharmacology Cardiology and Cardiovascular Medicine business medicine.drug
Zdroj:	Atherosclerosis Supplements. 11:175-176
ISSN:	1567-5688
DOI:	10.1016/s1567-5688(10)70830-8
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::52a0eab4c6c8832306ae349a967b5d44 https://doi.org/10.1016/s1567-5688(10)70830-8 Zobrazit plný text záznamu Full Text from ScienceDirect